Canopy Growth Q1 Revenue Drops 13% YoY, Reports Wider Net Loss
Canopy Growth Q1 Revenue Drops 13% YoY, Reports Wider Net Loss
"The fundamentals of our business continue to strengthen, and our focus on profitable revenue generation is yielding clear results as we set the stage for growth in the second half of fiscal 2025," Canopy Growth Corporation (TSX:WEED) (NASDAQ:CGC) announced its financial results Friday for the first quarter ended June 30, 2024.
2024年6月30日結束的第一季度，Canopy Growth Corporation (TSX: WEED) (NASDAQ:CGC)宣佈了其財務業績。
The Canadian cannabis giant reported a record quarter for Canadian medical marijuana, with new revenue surging 20% year-over-year and representing the 6th consecutive quarter of growth.
作爲加拿大大型大麻公司，報告了加拿大醫療大麻創紀錄的季度，新營收同比增長20%，連續6個季度增長。
In addition, the company has been ramping up its efforts to expand in the U.S. market via the Canopy USA business unit.
此外，該公司一直在通過Canopy USA業務部門擴張美國市場。
"The fundamentals of our business continue to strengthen, and our focus on profitable revenue generation is yielding clear results as we set the stage for growth in the second half of fiscal 2025," David Klein, the company's CEO, said. "With our core businesses delivering adjusted EBITDA profitability and primed for growth, paired with Canopy USA's positioning to benefit from near-term market opportunities in the U.S., Canopy Growth is advancing rapidly and is well established for multi-market cannabis leadership."
公司CEO David Klein表示：「我們業務的基本面繼續加強，我們專注於盈利的營收生成正取得明顯成果，爲2025財年下半年的增長打下基礎，隨着我們的核心業務實現調整後的EBITDA盈利能力並準備增長，以及Canopy USA定位有利於受益於美國短期市場機遇，Canopy Growth正迅速發展並在多元化市場大麻產業佔據領導地位。」
Q1 2025 Financial Highlights
2025財年第一季度財務亮點
- Net revenue declined by 13% year-over-year to CA$66.2 million ($48.1 million) driven mostly by the impact of divested businesses.
- Achieved gross profit was CA$23 million representing a 67% increase over the first quarter ended June 30, 2023, despite a decline in consolidated net revenue.
- Delivered consolidated gross margin of 35%, and Canada cannabis segment gross margin of 32% during the period.
- Operating loss from continuing operations was CA$29 million, representing a 47% year-over-year improvement.
- Net loss from continuing operations CA$129.2 million, representing a year-over-year increase of 1.122%.
- Consolidated adjusted EBITDA came in negative at CA$5.3 million, representing a 77% improvement year-over-year.
- Storz & Bickel net revenue increased 2% year-over-year, led by over 100% growth in Storz & Bickel sales in Germany, which offset a sales decline in the non-medical vaporizer channel in Australia following a regulatory change.
- Selling, general and administrative expenses were CA$48 million, representing a decrease of 24% year-over-year in part due to continued spending discipline across the organization.
- Free cash flow was an outflow of CA$56 million, an improvement of 49% year-over-year.
- 淨收入同比下降13%，至CA$66.2百萬（約合$48.1百萬），主要是受到出售業務影響。
- 實現的毛利潤爲CA$23百萬，同比增長67%，儘管綜合淨收入下降。
- 本期實現的綜合毛利率爲35%，加拿大大麻業務部門毛利率爲32%。
- 持續經營業務的營業虧損爲CA$29百萬，同比改善47%。
- 持續經營業務的淨虧損爲CA$129.2百萬，同比增加1.122%。
- 集團調整後的EBITDA合計爲CA$530萬，同比改善77%。
- Storz&Bickel的淨營收同比增長了2%，主要由於德國Storz&Bickel銷售增長100%，抵消了澳大利亞非醫用霧化吸入器渠道銷售下降。
- 銷售、一般及管理費用爲CA$48百萬，同比減少24%，部分原因是公司在整個組織範圍內繼續保持支出的嚴格控制。
- 自由現金流爲流出的CA$560百萬，同比改善49%。
CGC Price Action
CGC股價行爲
Canopy's shares traded 8.38% lower at $6.32 per share at the time of writing on Friday morning.
週五早上股票價格爲每股$6.32，Canopy股票現已下跌8.38%。
Read Next
閱讀下一篇
- What's Going On With Canopy Growth Stock After Earnings?
- Canopy Growth收盤之後的股價爲何會發生變化？
譯文內容由第三人軟體翻譯。